Presentations on CBER Research Programs

Bacterial risk control strategies to enhance the safety and availability of platelets for transfusion. Potential reclassification of nucleic acid and serology-based point-of-care and laboratory-based in vitro diagnostic devices indicated for use as aids in the diagnosis of human immunodeficiency virus (HIV) infection.

Reclassification of certain Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) diagnostics. Presentations about research programs at the FDA's Center for Biologics Evaluation and Research (CBER).

Bacterial risk control strategies for transfusion, device classification of human leukocyte antigen, human platelet antigen, and human neutrophil antigen devices, strategies to reduce the risk of transfusion-transmitted Zika virus, information on the Transfusion Transmissible Infections Monitoring System, and information on the FDA public workshop on emerging tick-borne diseases and blood safety

1) Recombinant Human Coagulation Factor IX, GlycoPEGylated 2) Blood Donor Deferral Policy for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products 3) Research programs in the Laboratory of Emerging Pathogens in the Division of Emerging Transfusion-Transmitted Diseases

Strategies to manage iron deficiency with blood donation; Adverse reactions in teen donors; Zika and blood safety; Workshop updates

Strategies for iron deficiency with blood donation; adverse reactions with teenage donors; informational session on Zika virus; and presentations on 1) The Transfusion Transmissible Infections Monitoring System, 2) FDA workshops on new methods to predict immunogenicity of therapeutic coagulation and on preclinical evaluation of red blood cells for transfusion